Lack of erectogenic activity of a novel selective melanocortin-4 receptor agonist in a clinical experimental model

J Clin Pharmacol. 2008 Oct;48(10):1237-41. doi: 10.1177/0091270008320925. Epub 2008 Jun 16.

Authors

Rajesh Krishna¹, Peggy Wong, Catherine Stevens, Inge De Lepeleire, Kristien Van Dyck, Raymond C Rosen, Isaias Noel Gendrano 3rd, Mathieu Peeters, John A Wagner, Gary A Herman

Affiliation

¹ Department of Clinical Pharmacology, Merck Research Laboratories, Mailstop RY34-A500, 126 East Lincoln Avenue, Rahway, NJ 07065-0900, USA. rajesh_krishna@merck.com

PMID: 18559488
DOI: 10.1177/0091270008320925

No abstract available

Publication types

Comparative Study
Randomized Controlled Trial

MeSH terms

Adult
Cross-Over Studies
Dose-Response Relationship, Drug
Double-Blind Method
Erectile Dysfunction / drug therapy*
Humans
Male
Middle Aged
Piperazines / pharmacology
Purines / pharmacology
Receptor, Melanocortin, Type 4 / antagonists & inhibitors*
Sildenafil Citrate
Sulfones / pharmacology
Vasodilator Agents / pharmacology

Substances

Piperazines
Purines
Receptor, Melanocortin, Type 4
Sulfones
Vasodilator Agents
Sildenafil Citrate